Rachel Vatnsdal
Stock Analyst at JP Morgan
(3.32)
# 964
Out of 5,169 analysts
68
Total ratings
53.19%
Success rate
15.05%
Average return
Main Sectors:
Stocks Rated by Rachel Vatnsdal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RVTY Revvity | Maintains: Neutral | $100 → $105 | $87.37 | +20.18% | 5 | Feb 3, 2026 | |
| ADPT Adaptive Biotechnologies | Maintains: Overweight | $17 → $20 | $13.39 | +49.37% | 6 | Nov 6, 2025 | |
| HSIC Henry Schein | Maintains: Overweight | $80 → $76 | $74.87 | +1.51% | 4 | Aug 7, 2025 | |
| AVTR Avantor | Maintains: Overweight | $17 → $14 | $7.80 | +79.49% | 1 | Aug 4, 2025 | |
| ILMN Illumina | Maintains: Neutral | $85 → $100 | $120.84 | -17.25% | 1 | Aug 1, 2025 | |
| CAI Caris Life Sciences | Initiates: Overweight | $31 | $18.54 | +67.21% | 1 | Jul 14, 2025 | |
| TXG 10x Genomics | Maintains: Neutral | $12 → $9 | $18.09 | -50.25% | 4 | May 9, 2025 | |
| TWST Twist Bioscience | Maintains: Underweight | $40 → $33 | $47.28 | -30.20% | 2 | May 6, 2025 | |
| RGEN Repligen | Maintains: Overweight | $200 → $190 | $119.27 | +59.30% | 6 | Apr 29, 2025 | |
| NVST Envista Holdings | Maintains: Neutral | $20 → $19 | $26.05 | -27.06% | 4 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $380 → $390 | $296.99 | +31.32% | 4 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $50 → $55 | $50.84 | +8.18% | 3 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $55 | $88.75 | -38.03% | 1 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $165 → $160 | $112.75 | +41.91% | 6 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $650 → $670 | $472.71 | +41.74% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $17 → $20 | $4.78 | +318.41% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,300 → $1,400 | $1,206.72 | +16.02% | 2 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.38 | - | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $60 → $90 | $33.74 | +166.75% | 2 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $250 → $270 | $195.21 | +38.31% | 4 | Dec 20, 2023 |
Revvity
Feb 3, 2026
Maintains: Neutral
Price Target: $100 → $105
Current: $87.37
Upside: +20.18%
Adaptive Biotechnologies
Nov 6, 2025
Maintains: Overweight
Price Target: $17 → $20
Current: $13.39
Upside: +49.37%
Henry Schein
Aug 7, 2025
Maintains: Overweight
Price Target: $80 → $76
Current: $74.87
Upside: +1.51%
Avantor
Aug 4, 2025
Maintains: Overweight
Price Target: $17 → $14
Current: $7.80
Upside: +79.49%
Illumina
Aug 1, 2025
Maintains: Neutral
Price Target: $85 → $100
Current: $120.84
Upside: -17.25%
Caris Life Sciences
Jul 14, 2025
Initiates: Overweight
Price Target: $31
Current: $18.54
Upside: +67.21%
10x Genomics
May 9, 2025
Maintains: Neutral
Price Target: $12 → $9
Current: $18.09
Upside: -50.25%
Twist Bioscience
May 6, 2025
Maintains: Underweight
Price Target: $40 → $33
Current: $47.28
Upside: -30.20%
Repligen
Apr 29, 2025
Maintains: Overweight
Price Target: $200 → $190
Current: $119.27
Upside: +59.30%
Envista Holdings
Mar 6, 2025
Maintains: Neutral
Price Target: $20 → $19
Current: $26.05
Upside: -27.06%
Mar 6, 2025
Maintains: Neutral
Price Target: $380 → $390
Current: $296.99
Upside: +31.32%
Feb 25, 2025
Downgrades: Neutral
Price Target: $50 → $55
Current: $50.84
Upside: +8.18%
Feb 21, 2025
Maintains: Overweight
Price Target: $50 → $55
Current: $88.75
Upside: -38.03%
Nov 26, 2024
Maintains: Overweight
Price Target: $165 → $160
Current: $112.75
Upside: +41.91%
Sep 20, 2024
Maintains: Overweight
Price Target: $650 → $670
Current: $472.71
Upside: +41.74%
Aug 7, 2024
Maintains: Underweight
Price Target: $17 → $20
Current: $4.78
Upside: +318.41%
Aug 5, 2024
Maintains: Neutral
Price Target: $1,300 → $1,400
Current: $1,206.72
Upside: +16.02%
Apr 22, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.38
Upside: -
Feb 14, 2024
Upgrades: Overweight
Price Target: $60 → $90
Current: $33.74
Upside: +166.75%
Dec 20, 2023
Maintains: Overweight
Price Target: $250 → $270
Current: $195.21
Upside: +38.31%